Jardiance and Hormonal Contraceptives: Drug Interaction Guide

Jardiance (empagliflozin) is an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. "Hormonal contraceptives" is a broad category that includes combined oral pills, progestin-only pills, the contraceptive patch and ring, the levonorgestrel IUD, the etonogestrel implant, and depot medroxyprogesterone acetate (DMPA) injections. These products differ enough in hormone dose and delivery route that they should not be treated as a single interaction question.

Is there a pharmacokinetic interaction? What the label supports

Empagliflozin is metabolized mainly by glucuronidation (UGT1A3, UGT1A8, UGT1A9, UGT2B7) rather than by cytochrome P450 enzymes. This matters because most drug interactions involving combined hormonal contraceptives run through CYP3A4 induction or inhibition, and empagliflozin does not meaningfully affect that pathway. The FDA-approved prescribing information for Jardiance states that the drug is not a clinically significant inhibitor or inducer of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or P-glycoprotein at approved doses. [FDA label]

The label also describes a pharmacokinetic study in which empagliflozin was co-administered with a combined oral contraceptive (ethinylestradiol plus levonorgestrel). According to the label, this study did not find a meaningful change in the pharmacokinetics of either steroid, and the label states no contraceptive dose adjustment is needed. We have not independently re-verified the exact numeric exposure ratios reported in that study against the current label text, and a reviewer should confirm the precise figures before they are quoted verbatim in patient materials. The directional conclusion, no clinically significant pharmacokinetic interaction, is what the label supports and is the load-bearing claim here.

Empagliflozin is also a substrate of OAT3 and P-glycoprotein for renal elimination. Drugs like probenecid (an OAT3 inhibitor) can raise empagliflozin exposure. Hormonal contraceptives are not known OAT3 inhibitors at physiologic concentrations, so this transporter route is not a plausible source of interaction here.

Can hormonal contraceptives still change how well Jardiance controls blood sugar?

This is the more clinically relevant question for a woman with diabetes, and it is a pharmacodynamic question rather than a pharmacokinetic one. Two drugs can have no effect on each other's blood levels and still produce a combined effect that differs from either drug alone.

Estrogen-progestin combinations have long been associated with modest reductions in insulin sensitivity in the contraceptive and endocrinology literature, with the effect size varying by progestin androgenicity and estrogen dose. This is a well-established general pattern in the contraceptive literature, though the specific studies and effect sizes describing it should be checked against current primary sources before being cited with precise numbers. The practical implication is straightforward: a person using empagliflozin for glycemic control who starts or switches a combined hormonal contraceptive may see some drift in glucose control, and this is worth checking rather than assuming away.

Progestin-only methods differ. The levonorgestrel IUD delivers hormone locally with low systemic absorption relative to an oral pill, which limits systemic metabolic effects, and the copper IUD has no hormonal activity at all. DMPA injections are the outlier in this group; DMPA has been linked in some observational research to worsening insulin resistance and higher progression to type 2 diabetes in women with a prior history of gestational diabetes. The exact magnitude of that association needs verification against the primary study before being restated as a fixed percentage, but the direction of the signal is consistent enough to warrant closer glucose monitoring when DMPA and an SGLT2 inhibitor are used together.

Professional guidance in this space (for example, the American Diabetes Association's Standards of Care) generally supports not withholding hormonal contraception from women with diabetes, while recommending closer glycemic monitoring around initiation or switching of methods, particularly when HbA1c is not at goal. Readers and clinicians should confirm the current-year Standards of Care document directly, since guideline language is updated annually.

Does Jardiance raise infection risk that hormonal contraceptives could compound?

Empagliflozin causes glycosuria by design, and glucose-rich urine and vaginal secretions support Candida growth. Empagliflozin trials have reported meaningfully higher rates of vulvovaginal candidiasis compared with placebo, and this is one of the most consistent adverse effects across the SGLT2 inhibitor class. Estrogen-containing contraceptives are separately associated with increased vaginal Candida colonization in the gynecologic literature. No controlled trial that we can point to here has quantified the combined risk of using both at once, so the additive effect is a plausible inference, not an established number. Women starting this combination should be counseled to report itching, discharge, or dysuria promptly.

Jardiance's label also notes a modest increase in urinary tract infections, more pronounced in women, across its trial program. Hormonal contraceptives are not known to add a distinct mechanistic UTI risk through the glucosuric pathway, though behavioral factors such as intercourse frequency are a separate, non-pharmacologic consideration.

Does the choice of contraceptive matter for clotting risk in someone on Jardiance?

Combined hormonal contraceptives, particularly those with drospirenone, desogestrel, or gestodene, carry an established increase in venous thromboembolism risk relative to non-use; this is a contraceptive-specific risk documented in the reproductive health literature and is not created or amplified by empagliflozin. Empagliflozin has shown cardiovascular benefit signals in outcome trials, but those findings do not translate into an anti-clotting effect that offsets contraceptive VTE risk, and there is no evidence that empagliflozin either raises or lowers a contraceptive's clotting risk.

For women with diabetes who already carry elevated baseline cardiovascular or thrombotic risk, for example those with nephropathy or established cardiovascular disease, choosing a lower-VTE contraceptive option (copper IUD, levonorgestrel IUD, progestin implant, or progestin-only pill) is a reasonable clinical preference independent of whether they are also taking empagliflozin.

What the FDA label says, and what still needs verification before quoting it

The current Jardiance prescribing information includes a drug interaction section that names specific interactions requiring attention: rifampicin (a UGT inducer that can reduce empagliflozin exposure), probenecid (an OAT3 inhibitor that can raise empagliflozin exposure), and concomitant diuretics or insulin/sulfonylureas (which raise volume depletion or hypoglycemia risk when combined with empagliflozin). Hormonal contraceptives are described in the label's dedicated interaction study as not requiring dose adjustment, based on the pharmacokinetic study discussed above. Anyone drafting patient-facing language from this label should pull the exact current-revision text directly from the FDA site rather than relying on a secondhand quotation, since label language is updated periodically and a stale quotation can misstate a current warning.

Empagliflozin is not recommended during pregnancy and the label recommends discontinuation once pregnancy is detected, due to potential fetal renal effects observed in animal studies at drug exposures relevant to human dosing. Women with diabetes taking empagliflozin who are considering stopping contraception to conceive should coordinate that transition with their prescriber, since most clinicians move patients to insulin or metformin before or immediately upon conception rather than continuing an SGLT2 inhibitor through pregnancy.

Evidence-status interaction assessment

What is established, what is plausible, and what remains unclear

Established: empagliflozin does not meaningfully alter the metabolism of ethinylestradiol or levonorgestrel, based on the pharmacokinetic study cited in its FDA label, and the label does not require a contraceptive dose change on that basis. Plausible but not proven as a combined effect: that using an estrogen-containing contraceptive alongside empagliflozin meaningfully raises yeast infection risk beyond either exposure alone, and that specific progestins produce quantifiable, contraceptive-by-contraceptive glucose effects large enough to require a fixed monitoring protocol. Not established from the material reviewed here: any precise combined risk percentage for infection or glycemic drift when the two drug classes are used together, since no trial identified in this review studied that combination directly.

Anyone using this article to counsel a patient should treat the pharmacokinetic conclusion as label-supported and treat the pharmacodynamic and infection-risk discussion as reasoned inference from separate bodies of evidence, not as a single validated combined-risk figure.

When to seek urgent care

Signs of diabetic ketoacidosis, including nausea, vomiting, abdominal pain, unusual fatigue, or difficulty breathing, even with a normal or only mildly elevated blood glucose, warrant urgent evaluation in anyone taking empagliflozin, regardless of contraceptive use. Heavy vaginal bleeding, calf swelling or pain, sudden shortness of breath, or chest pain in someone using a combined hormonal contraceptive warrants urgent evaluation for possible thromboembolism, independent of empagliflozin.

Frequently asked questions

References

1. U.S. Food and Drug Administration. Jardiance (empagliflozin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf

Additional claims in this article referencing contraceptive metabolic effects, DMPA and diabetes progression, venous thromboembolism risk by progestin, and PCOS trial data were present in the original source but could not be independently verified against a confirmed primary reference for this draft. These points have been described in general, directional terms rather than with specific citation numbers, and a clinical reviewer should locate and confirm primary sources before any precise statistic from those sections is published.